If you purchased or acquired securities in AstraZeneca between between February 23, 2022 and December 17, 2024 and would like ...

The AstraZeneca PLC ADR AZN slipped 1.27% to $69.86 Monday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ Composite Index COMP falling 1.20% to ...

AstraZeneca PLC closed 15.78% below its 52-week high of £133.88, which the company achieved on September 3rd.

Britain on Monday hit back at AstraZeneca over the collapse of a 450 million pound ($558.5 million) investment, saying the drugmaker had scaled back the research and development portion of its plans, ...

AstraZeneca scrapped plans for a £450 million UK vaccine plant after rejecting a £78 million government offer, citing ...

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Astrazeneca (AZN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the ...

In a report released today, James Gordon from J.P. Morgan maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target ...

Angle (LON:AGL) is a small share that's skyrocketed in recent weeks. Why does this investor hold the high-risk penny stock?

(Alliance News) - AstraZeneca PLC on Monday said Imfinzi has been recommended for approval in the EU as monotherapy for limited-stage small cell lung cancer.

For the first half of the fiscal year, analysts anticipate organic sales growth of 0.5%, net sales of $10.7bn and a 2% ...

A revival in AstraZeneca Plc shares faces a key test this week, with more likely to hinge on the drugmaker’s ability to ...

Great Diamond Partners LLC decreased its position in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 7.2% during the ...